|
Dr. Philippe Pouletty is a Biotech industry veteran with dual experience in Silicon Valley and France.
Founder of 3 biotechnology companies (two are public).
- SangStat, est. 1988 (California), quoted on NASDAQ in 1993 (first French quoted Biotech), CEO until 1998. Organ transplantation therapeutics. Sold to Genzume for 0 m cash, August 2003.
- Conjuchem, est. 1993 (California), quoted in Canada in 2000. Drug delivery and discovery. Best 2003 performer of Toronto Stock Exchange.
- DrugAbuse Sciences, est. 1995 (USA + France). Medications to treat alcohol and drug abuse.
President of France Biotech (French Biotech Industry Association) and vice chairman of Europabio (European Biotech Industry Association).
Limited partner of US VC funds, Sequoia, Sofinnova, Partech, JP Morgan.
MD from University of Paris V, MS degrees in immunology and virology from Pasteur Institute, post-doctoral research fellow at Stanford University, 1999 laureate of the American Liver Foundation. Inventor of 22 patents.
Board member of BMD, Chairman of the Board of Neovacs.
|
|
|
